UNSPSC 51422333: Dexamethasone acetate

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E2287TKU04. European Medicines Agency schedules Dexamethasone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01608MIG. Dexamethasone acetate generally arises in the molecular formula C24H31FO6. The term 'dexamethasone acetate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule dexamethasone acetate under HS 29372200 and SITC 54153.

Dexamethasone acetate bears US NLM identifiers UMLS ID C0057598 and NCI Concept Code C1067. SMILES: As of Q4 2014, DEXAMETHASONE ACETATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51422333 Dexamethasone acetate is a Commodity code that nominally covers a specific corticosteroid pharmaceutical, but the most recent state and local solicitation tagged under this code does not involve dexamethasone acetate at all. Seminole County, Florida issued IFB 60459723LAS seeking procurement of naloxone (an opioid antagonist) and drug deactivation systems — products wholly outside the scope of the code's stated pharmaceutical. The mismatch suggests either a data-entry error in the source record or misalignment between the code taxonomy and the actual procurement. No additional state or local opportunities under UNSPSC 51422333 appear in the available recent activity, and the single opportunity present is not related to the code's nominal scope.

The Seminole County naloxone and drug deactivation systems procurement, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with an optional one-year renewal, runs on a fixed-fee basis, and requires vendors to meet drug-free workplace certification, E-Verify compliance, and various insurance requirements including workers' compensation and commercial general liability. No explicit set-aside designations are stated. The procurement is potentially funded through FEMA and subjects vendors to federal compliance audits under the Clean Air Act and Federal Water Pollution Control Act. Given the absence of relevant recent activity for dexamethasone acetate procurement itself, this code does not present a clear pursuit opportunity for firms focused on the actual pharmaceutical product.